Sign in

José Molina

@josemolinagb.bsky.social
1.7K followers 787 following 191 posts

ID doc & Antibiotic Steward • • Clinical trials and #FOAMed believer • ESCMID Guidelines Subcommittee. Now on @shorten2trial.bsky.social #AMSsky #IDSky #AMR Hospital Virgen del Rocío • Seville, Spain 🇪🇸

PostsRepliesMedia
José Molina @josemolinagb.bsky.social · 30/09/2026
Bad news for patients with MDR infections… Merck has announced that imipenem/relebactam supply will be discontinued in US by the end of September. Guess this will extend to Europe soon? We definitely need new payment models for antibiotics 🙁 www.cidrap.umn.edu/antimicrobia... #IDsky #AMSsky #AMR
Source: https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Imipenem%20Anhydrous%2C%20Cilastatin%2C%20and%20Relebactam%20Anhydrous%20Injection&st=d
155
Reposted by José Molina
Clinical Microbiology and Infection @cmijournal.bsky.social · 28/09/2026
📣 In the October 2026 issue: The @escmid.bsky.social framework for reaching consensus in clinical guidelines www.clinicalmicrobiologyandinfection.org/article/S119... #IDSky #MicroSky
022
Reposted by José Molina
Angela Huttner @angelahuttner.bsky.social · 09/09/2026
Hi Gabriele! Guess what- with @germhuntermd.bsky.social & quite a few others, we are gearing up to launch an #IDjournalclub on Bsky and it looks like this paper is the one we'll start with. 😊 We will get that going soooon!! (Also, Communicable will work on a follow-up POET2 ep!) #IDSky #MedSky
3224
José Molina @josemolinagb.bsky.social · 20/09/2026
I find cefepime very useful to diversify empiric antipseudomonal treatments among immunocompromised hosts, and as a carbapenem-sparing agent against ampC producers. This recent metaanalysis made me wonder if I should stop using it… 🧵(1/5) jamanetwork.com/journals/jam... #IDSky #AMSsky #IDOnc
jamanetwork.com
Cefepime and Mortality
This systematic review with bayesian meta-analysis of randomized clinical trials examined the association of cefepime with all-cause mortality compared with other β-lactam antibiotics.
2126
José Molina @josemolinagb.bsky.social · 17/09/2026
So timely! 🤩
021
Reposted by José Molina
ADVANcing Clinical Evidence in Infectious Diseases (ADVANCE-ID) @advance-id.bsky.social · 14/08/2026
Demystify clinical trial design & enhance your research toolkit!📊✨ Join our statistical seminars supported by @advance-id.bsky.social & @who.int Explore clinical trial theory & real-life examples with global experts. Master the numbers in the mission against disease here: ad-id.co/stats
1129
Reposted by José Molina
Catherine Berry (she/her) @catherineberry.bsky.social · 14/09/2026
This was what was developed in response to the conference presentation which coincided with our flu season. livingevidence.org.au/influenza/
livingevidence.org.au
Influenza - Australian Living Evidence Collaboration
More information coming soon
131
Reposted by José Molina
José Molina @josemolinagb.bsky.social · 13/09/2026
Preprint of REMAP-CAP trial on oseltamivir for critical patients is now available: papers.ssrn.com/sol3/papers.... With this new trial + 2 recent metaanalyses failing to prove benefits in outpatients nor hospitalized, how is your center positioning oseltamivir for this flu season? #IDsky #PulmSky
papers.ssrn.com
Oseltamivir for Critically Ill Patients with Influenza: A Randomised Trial
​Background: The antiviral oseltamivir is widely used for the treatment of critically ill patients with influenza. Evidence from randomised trials about its eff
163
Reposted by José Molina
Juan E. Losa @juanelosag.bsky.social · 11/07/2026
Sobre la importancia de programas específicos de optimización de antibioterapia (PROA) en oncología… jamanetwork.com/journals/jam...
jamanetwork.com
Antibiotic Selection for Patients With Cancer Hospitalized With Infection
This secondary analysis of the 4 Intelligent Stewardship Prompts to Improve Real-Time Empiric Antibiotic Selection (INSPRE) cluster randomized clinical trials evaluates the association of computerized...
043
Reposted by José Molina
ASHE Journal @ashejournal.bsky.social · 14/07/2026
Part 1 of a two-part series on outpatient antimicrobial stewardship interventions in immunocompromised patients: what has been studied, what are barriers to implementing interventions in this group, and how ASPs might overcome these challenges. doi.org/10.1017/ash....
011
José Molina @josemolinagb.bsky.social · 12/07/2026
Remdesivir and a monoclonal antibody (MBP134) will be tested against SOC. www.who.int/news/item/02... #IDsky Amazing PARTNERS initiative. Being able to run an adaptive platform trial in this situation is so needed and yet so impressive. Hats off for the team! @who.int
who.int
Patient enrolment begins in a scientific trial to identify the first effective treatments for Bundibugyo virus disease
In a major international effort to evaluate potential treatments for Ebola disease due to Bundibugyo virus (BVD), the PARTNERS clinical trial has opened enrolment today for patients in the Democratic ...
062
José Molina @josemolinagb.bsky.social · 12/07/2026
A (not so) new kid on the block! Temocillin proved non-inferior to carbapenems against 3GR-Enterobacterales. Hope to see this old drug widely available in Europe soon! 🤞🏻 www.thelancet.com/journals/lan... #AMSsky #IDsky
thelancet.com
Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clini...
In patients with bacteraemia caused by 3GCR-E, temocillin was non-inferior to carbapenems as targeted treatment. These findings support the use of temocillin as an effective and safe alternative to ca...
0113
Reposted by José Molina
Quique Carús @quiquecarus.bsky.social · 09/07/2026
c.org/NjjyxpJb68
c.org
Firma la petición
Creación especialidad enfermedades infecciosas como en el resto de la Unión Europea ¡YA!
011
Reposted by José Molina
Gabriele Pollara @gpollara.bsky.social · 09/07/2026
Disappointing data on meningitis vaccine preventing Neisseria gonorrhoea infections Then again negative trial data is as useful as positive findings, so that we focus resources most effectively #IDSky www.nejm.org/doi/full/10....
nejm.org
Meningococcal B Vaccine to Prevent Neisseria gonorrhoeae Infection | NEJM
No vaccines are currently licensed for the prevention of Neisseria gonorrhoeae infection. Observational studies suggest that the four-component meningococcal serogroup B vaccine (4CMenB) may reduce...
12411
José Molina @josemolinagb.bsky.social · 07/07/2026
Nurses boost AMS! #UTIsky #AMSsky
151
José Molina @josemolinagb.bsky.social · 07/07/2026
Immunocompromised hosts should not be excluded from duration trials. The question is how we can safely incorporate them into these studies to generate the evidence we need. Our editorial in @cmijournal.bsky.social is freely available here: 🔓 authors.elsevier.com/a/1nOm-,RGPg... #IDsky #TxID #IDOnc
authors.elsevier.com
Please wait whilst we redirect you
All content on this site: Copyright © 2026 Elsevier B.V., its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
0123
Reposted by José Molina
id-journal.bsky.social @id-journal.bsky.social · 07/07/2026
EcoRxChoice 🌍💊 lets users compare plastic waste from antimicrobial regimens, promoting eco-friendly prescribing. Supported by SIDP to boost sustainable antimicrobial stewardship.
cambridge.org
EcoRxChoice.com— an SIDP-funded calculator integrating environmental metrics with antimicrobial stewardship
View abstract Healthcare sustainability is a multidisciplinary field that seeks to mitigate healthcare’s environmental consequences. Antimicrobial stewardship and healthcare sustainability both aim to reduce wasteful resource use while maximizing patient safety. However, a strong partnership between antimicrobial stewardship and healthcare sustainability has yet to develop. To facilitate environmentally sustainable decision-making in antimicrobial prescribing, we developed a web-based calculator (EcoRxChoice (www.ecorxchoice.com)) where users can enter different antimicrobial regimens and compare how much plastic waste each regimen creates. This work was supported in part by the Society of Infectious Diseases Pharmacists (SIDP), reflecting SIDP’s commitment to strengthening sustainability as a practical extension of antimicrobial stewardship and empowering infectious disease pharmacists to make measurable environmental impact through evidence-based care.
001
Reposted by José Molina
Clinical Microbiology and Infection @cmijournal.bsky.social · 06/07/2026
🌟 The 2025 JCR Impact Factor for CMI has risen to 8.7! We thank our editors, reviewers, authors and readers for their dedication and extraordinary work. Read about how CMI did in 2025 here: clinicalmicrobiologyandinfection.org/article/S119... #IDSky #MicroSky #JIF #JCR2025
064
Reposted by José Molina
NEJM.org @nejm.org · 01/07/2026
𝐍𝐞𝐰 𝐢𝐧 𝑵𝑬𝑱𝑴 𝑪𝒂𝒕𝒂𝒍𝒚𝒔𝒕 𝑰𝒏𝒏𝒐𝒗𝒂𝒕𝒊𝒐𝒏𝒔 𝒊𝒏 𝑪𝒂𝒓𝒆 𝑫𝒆𝒍𝒊𝒗𝒆𝒓𝒚! HealthPartners’ Antimicrobial Stewardship Program demonstrates the potential of centralized complex outpatient antibiotic therapy programs to optimize patient care. Learn more: nej.md/4uEs79k Explore the July issue: nej.md/3QMDUo2
The image depicts an illustration related to an article published in NEJM Catalyst Innovations in Care Delivery. It shows three figures walking along winding paths that connect platforms labeled with the medical hospital symbol. The figures navigate a complex network, symbolizing the coordination of outpatient antibiotic therapy programs.
021
Reposted by José Molina
Steven Tong @steventong.bsky.social · 27/06/2026
We are genotyping and phenotyping the SNAP MSSA isolates for cefazolin inoculum effect. So we can look at cefazolin vs ASPs (randomized) treatment effect in CIE+, and compare to that in CIE-. I estimate several hundred (prob >400) in each CIE group.
2111
Reposted by José Molina
ACCP ID PRN @accpinfdprn.bsky.social · 26/06/2026
Looking for a new antimicrobial stewardship metric? 👀 Authors from the VA have proposed a new "S3" option, which assesses the initiation, spectrum, and duration of therapy. 📖 Read more here academic.oup.com/cid/advance-... #AntimicrobialStewardship
011
Reposted by José Molina
Andy Conway Morris @andymoz78.bsky.social · 23/06/2026
The implications of this work is that we need look into body compartments to understand the inflammatory responses and can't simply rely on blood. Further, we need to tailor our treatments to the mechanisms identified- a simple "pneumonia=treatment X" is not going to work.
041
Reposted by José Molina
Andy Conway Morris @andymoz78.bsky.social · 23/06/2026
Great to see our new paper out in Nature Communications. In it we describe three novel phenotypes in lungs of patients with pneumonia. Pn1 -a non-neutrophil driven lung injury phenotype, Pn2-a balanced immune response with best recovery and Pn3-persistent inflammation driven by immature neutrophils
rdcu.be
Pulmonary inflammation in severe pneumonia is characterised by compartmentalised and mechanistically distinct sub-phenotypes
Nature Communications - Analysis of cell samples from pneumonia patients may indicate specific phenotypes associated with disease. Here the authors use a multi-omics approach to analyse...
2189
Reposted by José Molina
John Ross @johnrossmd.bsky.social · 23/06/2026
Good news: C difficile diarrhea cases are decreasing in hospitals due to decreased antibiotic use Bad news: C difficile is increasing in the community, possibly due to widespread use of antibiotics in agriculture #IDSky
academic.oup.com
Validate User
073
José Molina @josemolinagb.bsky.social · 23/06/2026
The OASIS RCT comparing olorofim vs amphotericin B for azole-resistant aspergillosis met its primary endpoint of non-inferiority for mortality (23% vs 24%), with fewer AEs (36% vs 64%), according to company report: www.shionogi.com/global/en/ne... Looking forward to the publication! #IDsky #IDOnc
shionogi.com
F2G and Shionogi Announce Positive Topline Results from Global Phase 3 OASIS Study Evaluating Oral Olorofim Versus AmBisome® Followed by Standard of Care in Patients with Invasive Aspergillosis
094
José Molina @josemolinagb.bsky.social · 23/06/2026
Bringing #AMR into the outcome assessment of duration trials with the new DOOR-FRAME is very welcome! Larger samples and systematic AMR assessment among participants will be likely required to prove benefit academic.oup.com/ofid/article... #IDSky #AMSsky Awesome work by @seanong.bsky.social et al
081
Reposted by José Molina
Nature Portfolio @natureportfolio.nature.com · 23/06/2026
Plastic pollution is pervasive across ecosystems. A Review in Nature Reviews Biodiversity summarizes current evidence on plastic exposure pathways, organismal responses and potential effects at higher levels of biological organization. go.nature.com/3QsA6rS 🌎🧪
This is figure 1, which shows the interactions of plastic with biodiversity.
16625
Reposted by José Molina
Jonathan Ryder, MD @jonathanrydermd.bsky.social · 21/06/2026
Not all apples to apples. Editorial for this piece with a nice summary of available evidence for fosfomycin academic.oup.com/cid/advance-...
152
José Molina @josemolinagb.bsky.social · 21/06/2026
Antimicrobial Stewardship [vol.2] already running! Did we miss someone? 😉 #AMSsky #IDsky #MicroSky #PharmSky go.bsky.app/2qsEveQ
053
José Molina @josemolinagb.bsky.social · 19/06/2026
How could we define the best treatment duration for immunocompromised hosts? Happy to share our perspective in this editorial in @cmijournal.bsky.social, building on the recent BALANCE subanalysis for this vulnerable population www.sciencedirect.com/science/arti... #AMSsky #TxID #IDOnc #IDsky
sciencedirect.com
0117
Reposted by José Molina
Contagion® @contagionlive.bsky.social · 18/06/2026
The #FDA has approved #tebipenem pivoxil the first oral carbapenem antibiotic in the US for adults with complicated urinary tract infections. #IDsky #Medsky www.contagionlive.com/view/fda-app...
contagionlive.com
FDA Approves Tebipenem Pivoxil as First Oral Carbapenem For Complicated Urinary Tract Infections | Contagion Live
The FDA has approved tebipenem pivoxil (Utebzi), the first oral carbapenem antibiotic in the US for adults with complicated urinary tract infections (cUTIs), including pyelonephritis, providing an eff...
084
Reposted by José Molina
Antibiotic Steward 🅱️C🆔🅿️🌟 @absteward.bsky.social · 18/06/2026
Wow! 🆕🔥🔴Multicenter OL NI RCT Oral fosfomycin (3 g once daily) was noninferior to continued intravenous therapy with carbapenems or BLBLIs when used as oral transition therapy for complicated UTIs caused by ESBL-producing Enterobacterales #IDSky #utisky academic.oup.com/cid/article-...
academic.oup.com
Fosfomycin as Oral Transition Therapy Versus Continued Intravenous β-Lactams for Complicated Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase–Producing Enterobacterales: A Multicenter,...
Switching from intravenous antibiotics to oral fosfomycin was noninferior to continuing intravenous therapy for complicated urinary tract infections caused
22719
José Molina @josemolinagb.bsky.social · 17/06/2026
The SNAP trial domain on cefazolin vs cloxacillin for MSSA bacteremia is finally published! www.nejm.org/doi/full/10.... Cefazolin is already the new standard! #IDsky #AMSsky
0186
Reposted by José Molina
CMI Communications @cmicomms.bsky.social · 14/06/2026
🎙️ Just published Communicable E56: Frequentist vs Bayesian for clinical trial analysis – 99% probability you’ll want to listen to this Hosted by Emily McDonald & Josh Davis with invited guests Roger Lewis & Ian Marschner 🌟 Listen on #Communicable: share.transistor.fm/s/7ea020d2 #IDSky
0125
Reposted by José Molina
CMI Communications @cmicomms.bsky.social · 12/06/2026
📣 If you have questions about fosfomycin, we have answers! Excellent review article by Tiffany Wu, Kalpana Gupta, @erinmccreary.bsky.social, Sarah Turbett & Jacob Lazarus on oral #fosfomycin & how to use it. #IDSky #clinmicro #UTISky #Medsky #Pharmsky www.cmi-comms.org/article/S295...
cmi-comms.org
Oral fosfomycin tromethamine for UTI: Guidance for clinicians
Oral fosfomycin is a guideline-recommended first-line treatment for uncomplicated cystitis. However, fosfomycin has demonstrated lower clinical and/or microbiological cure rates compared with other an...
085
Reposted by José Molina
SHORTEN-2 trial @shorten2trial.bsky.social · 11/06/2026
There’s enough evidence from observational and RCT subgroups to stop excluding systematically immunocompromised hosts from duration trials. Uncomplicated source + early response should always mean shorter. 1 in 3 patients in @shorten2trial.bsky.social is inmunocompromised bsky.app/profile/jose...
062
Reposted by José Molina
Jonathan Ryder, MD @jonathanrydermd.bsky.social · 11/06/2026
Excited to share an article that I've long awaited to share seeking to answer: What is the right dose of cephalexin/cefadroxil for SSTIs? We reviewed clinical studies & conducted PTA sims to elucidate this #IDSky @absteward.bsky.social accpjournals.onlinelibrary.wiley.com/doi/10.1002/...
accpjournals.onlinelibrary.wiley.com
Getting It Right the Second Time: How Can we Optimize First‐Generation Cephalosporin Dosing for Skin and Soft Tissue Infections in the 21st Century?
Optimal cephalexin and cefadroxil dosing for skin and soft tissue infections (SSTIs) is unclear. We summarize clinical and pharmacokinetic/pharmacodynamic (PK/PD) data that compare dosing strategies ...
73515
José Molina @josemolinagb.bsky.social · 10/06/2026
REMAP-CAP domain on oseltamivir vs no-antiviral for patients admitted at ICU with influenza is stopped due to potential harm! 90d mortality: Oseltamivir=19.4% (62/319) No antiviral=13.7% (17/124) Last word for oseltamvir? What’s the rationale for harm? #IDSky www.remapcap.org/oseltamivir-...
remapcap.org
Oseltamivir Clinician FAQs — REMAP-CAP Trial
51610
Reposted by José Molina
NEJM.org @nejm.org · 31/05/2026
Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: nej.md/4nWaxvM #ASCO26
Graph from a study published in the New England Journal of Medicine on daraxonrasib versus chemotherapy for metastatic pancreatic cancer. The x-axis represents months, and the y-axis shows the percentage of patients alive. Two lines indicate survival rates: daraxonrasib (blue) and chemotherapy (gray). The bottom section lists patients at risk over time. Title and journal logo are included.
15030
Reposted by José Molina
Antibiotic Steward 🅱️C🆔🅿️🌟 @absteward.bsky.social · 29/05/2026
Cefepime/Zidebactam: Class: DBO Inhibitor + 4th-Gen Cephalosporin Potent PBP2 “Enhancer Effect". Broad serine beta-lactamases and complementary PBP binding against MBLs Demonstrated success in compassionate-use salvage therapy for extensively drug-resistant, NDM-producing P. aeruginosa #idsky
051
Reposted by José Molina
SHORTEN-2 trial @shorten2trial.bsky.social · 30/05/2026
SHORTEN2 results have been presented at #CongresoSEIMC2026! 7-day treatments were shown superior to 14-day in reducing antibiotic exposure and adverse events while maintaining efficacy. Fantastic work by >100 researchers across 37 Spanish hospitals! #TeamPride #IDsky #AMSsky @seimc.bsky.social
1114
Reposted by José Molina
Antibiotic Steward 🅱️C🆔🅿️🌟 @absteward.bsky.social · 29/05/2026
Amazing 😍 🔥SHORTEN 2 RCT A 7-day treatment course is superior to 14 days for uncomplicated Pseudomonas aeruginosa bacteremia, achieving similar clinical response rates with lower antibiotic exposure, fewer superinfections, and fewer serious adverse events #idsky @shorten2trial.bsky.social
3389
Reposted by José Molina
SHORTEN-2 trial @shorten2trial.bsky.social · 23/05/2026
We’re happy to share that results of the @shorten2trial.bsky.social will be presented at the #XXIXCongresoSEIMC! 📆 Friday, May 29 - 14:25h 📍Room 0D 📻 Stay tuned! #AMSsky #IDSky @absteward.bsky.social @idstewardship.bsky.social @bradspellberg.bsky.social @drtoddlee.bsky.social @esgap.bsky.social
085
Reposted by José Molina
Steven Tong @steventong.bsky.social · 14/05/2026
ESCMID 2026 highlights COBRA Trial – One day is enough Dutch RCT: 1 day of antibiotics after ERCP drainage for cholangitis was non‑inferior to 4–7 days. Bottom line: Antibiotic durations can safely be much shorter once source control is achieved. #IDSky clarityinitiative.org/escmid-2026-...
clarityinitiative.org
Clarity Initiative
Clinical Literature Appraisal and Research education in InfecTious diseases
13117
Reposted by José Molina
ESCMID @escmid.bsky.social · 25/05/2026
📣The Guidelines Subcommittee has an open call to train young professionals in guidelines production. It's free of charge, but participants commit to support projects after completing the course. ow.ly/lIyy50Z31c9 ⏰Apply by Friday! #IDSky #clinmicro
032
Reposted by José Molina
SHORTEN-2 trial @shorten2trial.bsky.social · 23/05/2026
Can we use short treatments for bacteremia in #SOT? This metaanalysis of observational data + SOT randomized in prior trials suggests the efficacy of short courses. We’ve got the rationale to stop excluding SOT from duration trials! onlinelibrary.wiley.com/doi/10.1111/... #IDSky #AMSsky #TxID
onlinelibrary.wiley.com
Outcomes of Short Antibiotic Courses for Gram‐Negative Bloodstream Infections in Solid Organ Transplant Recipients—A Systematic Review and Meta‐Analysis
In this meta-analysis of seven studies involving 249 solid organ transplant (SOT) recipients with Gram-negative bloodstream infections, no statistically significant differences in mortality or clinic....
063
Reposted by José Molina
Antibiotic Steward 🅱️C🆔🅿️🌟 @absteward.bsky.social · 21/05/2026
🆕💥🟢A contaminated dicloxacillin capsules in Europe triggered not only a clonal NDM-5/OXA-48 Enterobacter hormaechei outbreak, but also plasmid transfer to other Enterobacterales. Many cases were missed by standard strain-based outbreak methods #idsky #microsky www.thelancet.com/journals/lan...
thelancet.com
Gene transfer from NDM-5-producing and OXA-48-producing Enterobacter hormaechei ST79 on contaminated dicloxacillin capsules to other Enterobacterales in Europe, 2020–23: a retrospective, observational...
This study describes how a clonal CPE outbreak caused by a contaminated medicine evolved into a complex plasmid-mediated outbreak involving multiple Enterobacterales species. Most patients related to ...
056
Reposted by José Molina
ESCMID @escmid.bsky.social · 20/05/2026
📣We are now accepting applications for ESCMID Study Group research grants! Joining a study group is free and open to all ESCMID members. Our study groups cover a vast range topics eligible for funding. Propel your research to new heights! 💡Learn more: ow.ly/68VQ50Z23gP #IDSky #clinmicro
025
Reposted by José Molina
Antibiotic Steward 🅱️C🆔🅿️🌟 @absteward.bsky.social · 16/05/2026
🆕💥🔴Integral-1 RCT Efficacy and safety of cefepime–nacubactam and aztreonam–nacubactam compared with imipenem–cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis #idsky www.thelancet.com/journals/lan...
thelancet.com
Efficacy and safety of cefepime–nacubactam and aztreonam–nacubactam compared with imipenem–cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a doub...
Cefepime–nacubactam and aztreonam–nacubactam are potential treatment options for Gram-negative cUTI and acute uncomplicated pyelonephritis, including infections caused by antimicrobial-resistant strai...
032
Reposted by José Molina
Antibiotic Steward 🅱️C🆔🅿️🌟 @absteward.bsky.social · 02/05/2026
Not all β-lactamases are equal. Know your β-lactamase → Ambler classification made simple—in one image #IDSky #microsky Ref: www.mdpi.com/2079-6382/10...
0173